Patient & Survivor Care
From the Journals
Cancer pain declines with cannabis use
Lower use of other meds was also seen in patients who used cannabis.
Commentary
Some decisions aren’t right or wrong; they’re just devastating
One might wonder: Why is it so hard to do the right thing? Ask any clinician and I think you will hear the same answer: because we do not have the...
From the Journals
Better monitoring of cisplatin-induced ototoxicity needed
“Providing treating oncologists with a timely opportunity to alter therapy or providing patients with support, guidance, and earlier access to...
Conference Coverage
Guidelines for assessing cancer risk may need updating
Whole-exome sequencing reveals cancer risk mutations in patients that would not have qualified for testing based on current guidelines.
Conference Coverage
‘Exciting’ results for cancer vaccine plus pembro in melanoma
A new randomized study is the first to demonstrate improvement in recurrence-free survival in melanoma with an individualized neoantigen vaccine...
Conference Coverage
Racial disparities in cardiotoxicity after chemotherapy
“The most important message is to look at preexisting cardiovascular disease, oncology diagnosis, and be aware of existing disparities in a...
Conference Coverage
African ancestry genetically linked to worse CRC outcomes
Results from a new study provide greater clarity regarding the genetic piece of the puzzle.
Conference Coverage
AI predicts endometrial cancer recurrence
Model uses only digitized histopathology slides, but more validation in other populations is needed.
Conference Coverage
PARP/ATR inhibitor combo shows hints of promise in children with tumors
A phase 1 clinical trial could provide biomarker clues to help guide future studies.
Conference Coverage
Circulating DNA has promise for cancer detection, but faces challenges
Unnecessary procedures and health care challenges could leave Whites as the primary beneficiaries.
Conference Coverage
Pembrolizumab monotherapy effective for rare melanoma
Patients with unresectable desmoplastic melanoma experienced a response rate that was nearly double other melanomas.